Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
about
Exposure to a Mycobacterial Antigen, ESAT-6, Exacerbates Granulomatous and Fibrotic Changes in a Multiwall Carbon Nanotube Model of Chronic Pulmonary DiseaseGlycyrrhizic acid alleviates bleomycin-induced pulmonary fibrosis in ratsiTRAQ-Based Proteomics Reveals Novel Biomarkers for Idiopathic Pulmonary Fibrosis.Trichostatin A attenuates ventilation-augmented epithelial-mesenchymal transition in mice with bleomycin-induced acute lung injury by suppressing the Akt pathway.Relationship between plasma matrix metalloproteinase levels, pulmonary function, bronchodilator response, and emphysema severity.Club Cell Protein 16 (CC16) Augmentation: A Potential Disease-modifying Approach for Chronic Obstructive Pulmonary Disease (COPD)Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s).Immune Mechanisms in Pulmonary Fibrosis.Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis.Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis.Meprin β contributes to collagen deposition in lung fibrosis.Interplay of extracellular matrix and leukocytes in lung inflammation.Lung carcinogenesis and fibrosis taken together: just coincidence?Activation of MMPs in Macrophages by Mycobacterium tuberculosis via the miR-223-BMAL1 Signaling Pathway.Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score.The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis.Fibrin-Enhanced Canonical Wnt Signaling Directs Plasminogen Expression in Cementoblasts.Unsupervised gene expression analyses identify IPF-severity correlated signatures, associated genes and biomarkers.Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.Nickle(II) ions exacerbate bleomycin-induced pulmonary inflammation and fibrosis by activating the ROS/Akt signaling pathway.Metabolic characterization and RNA profiling reveal glycolytic dependence of profibrotic phenotype of alveolar macrophages in lung fibrosis.Senescence and aging: Causes, consequences, and therapeutic avenues.Neutrophils: a cornerstone of liver ischemia and reperfusion injury.MMP Activity Detection in Zymograms.Global Gene Expression Analysis in an in vitro Fibroblast Model of Idiopathic Pulmonary Fibrosis Reveals Potential Role for CXCL14/CXCR4.Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.Influence of the interaction between Ac‑SDKP and Ang II on the pathogenesis and development of silicotic fibrosis.4-1BB Signaling Promotes Alveolar Macrophages-Mediated Pro-Fibrotic Responses and Crystalline Silica-Induced Pulmonary Fibrosis in Mice
P2860
Q28390581-5A1867AE-C769-4C05-959B-D807E26077D0Q36109719-3DDDB024-613F-4445-930D-BC63BFCB9A32Q36259789-9A569AE5-6C17-4F5B-857A-F439AD9DF541Q36289784-76270722-906D-4BFE-AE61-8A5E0CC5E05CQ36961473-BB601072-090A-47E5-AE13-7B016F15B149Q37158751-722EE2C4-945F-40E6-987A-E099BD4AC45AQ38824212-F63EADFE-78F7-45FF-8032-7F86C0EA55FCQ38826634-94372CC7-3F4B-49F0-B9D6-77D368B5E412Q38913044-94376008-7144-430F-A46A-C1163CB80F7AQ39022184-FE41B4CA-E71D-4DA2-91F1-0BEE73E95764Q39036654-7228CE4A-810A-4377-A657-E8E2DBF6F4FBQ39080263-0D61B00A-79B7-4298-A5E2-B623FA885AF3Q39237924-CC9BD4B2-773A-4364-9CA0-185F51038A5AQ40198914-98539BB0-67A0-4EBE-BD5D-9505D7AE852AQ42282467-7112F356-10B3-401B-BF7A-E291A2323116Q42694416-FC55CE42-4BBB-4E60-ABC6-8C35C4ED5274Q46273924-A7BBCA22-4AA6-4EF8-A6A3-1D8A799EF3C2Q47111900-B6DECDA2-7D14-4836-A243-EEFA8DDEF84CQ47141068-7DF1206D-FEAC-4CD3-AD3C-6A5D37797AACQ47353514-55E94D50-0F58-4AE3-AE80-A2A077DC834BQ47804954-80364848-41AB-4888-BEED-3F4960FE4EC5Q48347290-32597EA5-2EE3-4194-9418-8F2C8182B10AQ50047875-09AD16EA-715B-4894-9CC6-DE283847FC13Q50170456-22AD7331-0900-4150-82D4-419829107D82Q52673165-B796B206-2DF9-4926-9B22-4803018EF5FEQ52721106-2E2352C2-5F9E-4939-8FC1-7242FE02FAD7Q55451084-442BAC78-C472-489B-9FD9-44EFC126FAD6Q58754498-599B77E0-C09A-4CF8-B953-D32F30EF6E26
P2860
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
@ast
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
@en
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
@nl
type
label
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
@ast
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
@en
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
@nl
prefLabel
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
@ast
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
@en
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
@nl
P2093
P2860
P921
P3181
P356
P1476
Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis
@en
P2093
Caroline A Owen
James S Hagood
Vanessa J Craig
P2860
P304
P3181
P356
10.1165/RCMB.2015-0020TR
P407
P577
2015-11-01T00:00:00Z